Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute ...

Although there is no cure for narcolepsy, medication and lifestyle changes can help manage the symptoms. Medicines that ...

The book, Uncancelable: The Incredible Rise of Mac G chronicles the podcaster’s journey from a young boy in Venda with a ...

RFK Jr, diagnosed with spasmodic dysphonia, is in the news for his confirmation hearing as the United States Secretary of ...

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system ...

Harmony Biosciences' Wakix shows promise for significant revenue growth. Find out why HRMY stock’s profitability and pipeline ...

AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...

Alkermes wants to augment its pipeline with M&A or licensing deals in serious mental illnesses and substance abuse. “I think anyone who's developing a drug in these spaces, they are probably better ...

Medicare covers sleep tests for certain conditions such as sleep apnea, narcolepsy, or parasomnia, but limitations may apply.

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda said it's laser-focused on six pipeline assets that could each reel in ...

The narcolepsy treatment market is set for substantial growth, with projections indicating an increase from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, reflecting a compound annual ...

Narcolepsy Treatment Market Narcolepsy Treatment Global Narcolepsy Treatment Market to Grow at 5.1% CAGR, Reaching USD 8,718.3 Million by 2034. Key Drivers Include Advanced Drugs, Devices, & Gro ...